A randomized placebo-controlled multi-dose Phase IIa trial for PRS-080 in FID anemia patients

Trial Profile

A randomized placebo-controlled multi-dose Phase IIa trial for PRS-080 in FID anemia patients

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs PRS 080 (Primary)
  • Indications Iron deficiency anaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Aug 2017 According to a Pharmaceuticals media release, the company is planning filing of separate clinical trial applications with the German and Czech Republic regulatory authorities to conduct this trial during this quarter.
    • 09 Jul 2017 New trial record
    • 05 Jul 2017 The company expects to enroll patients in this trial in the third quarter of 2017 according to a Pieris Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top